Close
Achema middle east
swop processing & packaging

Glenmark Pharma receives 2nd US FDA tentative approval for generic Onglyza tablets

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Korean Biopharma Market to Double Biopharma Exports By 2030

The South Korean government has gone on to hold...

Matica Bio Gets a U.S. Biotech Commercial Manufacturing Deal

Matica Biotechnology, Inc., which happens to be a leading...

The Latest Breakthroughs in Dental Treatments

Dental care has moved well beyond fillings and routine...

How Can Digital Tools Improve Medication Adherence in Patients?

Medication adherence has long been one of healthcare’s toughest...

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received a 2nd tentative approval by the United States Food & Drug Administration (FDA) for saxagliptin tablets, 2.5 mg and 5 mg, the generic version of Onglyza tablets, 2.5 mg and 5 mg, of AstraZeneca AB.

Glenmark’s first tentative approval letter for saxagliptin tablets, 2.5 mg and 5 mg was received on June 12, 2017.

According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza tablets, 2.5 mg and 5 mg market achieved annual sales of approximately $122.3 million.

Glenmark’s current portfolio consists of 179 products authorized for distribution in the US marketplace and 46 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals Ltd. is an innovation-driven, global pharmaceutical company with a presence across branded, generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.

Latest stories

Related stories

Korean Biopharma Market to Double Biopharma Exports By 2030

The South Korean government has gone on to hold...

Matica Bio Gets a U.S. Biotech Commercial Manufacturing Deal

Matica Biotechnology, Inc., which happens to be a leading...

The Latest Breakthroughs in Dental Treatments

Dental care has moved well beyond fillings and routine...

How Can Digital Tools Improve Medication Adherence in Patients?

Medication adherence has long been one of healthcare’s toughest...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »